Guggenheim upgraded Bristol Myers (BMY) to Buy from Neutral with a $62 price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Cautious Hold Rating on Bristol-Myers Squibb Amid Competitive Pressures in Hematology
- Bristol Myers says FDA grants priority review to sBLA for Opdivo
- Bristol Myers raises quarterly dividend 1.6% to 63c per share
- Bristol Myers price target raised to $53 from $50 at HSBC
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’